OBJECTIVES:  Deep Brain Stimulation (DBS), has shown motor symptoms and quality of life improvement in advance Parkinson Disease (PD). There is evidence that DBS could also be effective in PD with early motor complications, which must be reflected in longer time horizon to offset the initial costs and better quality adjusted life years (QALYs). We did a cost-utility analysis of DBS vs. Best Medical Treatment (BMT) in the management of PD patients with early motor complications in Colombia. METHODS:  After transferability analysis, adaptation of previously developed Markov model for cost-utility analysis was done. The Unified Parkinson's Disease Rating Scale measured “on_meds” was used to model disease progression and treatment effectiveness. Data was taken from the prospective EarlyStim-PD CT, including patient’s characteristics, effectiveness and adverse events (AE). Data was used for fall probability, utility values, BMT withdrawal. The 15-years rechargeable DBS device was assumed. Resource use and costs were gathered from official prices and KOL. Colombian Mortality rates, a 15 years horizon, 3,5% discount rate and payer perspective was assumed. All costs were converted to USDollars to allow international comparison. Univariate and probabilistic sensitivity analysis were done. RESULTS:  To 15 years, total discounted cost for DBS was estimated in USD$85.198 vs. USD$103.560 for BMT, (- USD$18.362). DBS yield 5,15 discounted QALYs compared to 4,10 for BMT, configuring dominance over BMT and not requiring to do incremental analysis. The main difference was obtained in medication costs, offsetting the DBS implantation costs. There were also savings in AE, follow up, falls, and other hospital costs. The univariate analysis showed the results were especially sensible to horizon. In the probabilistic analysis, 99,4% of iterations fall in the SE quadrant. CONCLUSIONS:  Compared to BMT, DBS yielded a higher total Quality of life to a lower total cost, generating costs savings in a 15 years horizon.